Genetically engineered bacterium for efficiently producing L-2-aminobutyric acid as well as construction method and application of genetically engineered bacterium

By constructing genetically engineered strains, knocking out and overexpressing specific genes, optimizing the metabolic pathway and energy supply of L-2-aminobutyric acid, the problems of low biomass and low titer in the prior art are solved, and the effect of efficient production of L-2-aminobutyric acid is achieved.

CN120005785APending Publication Date: 2025-05-16ZHEJIANG UNIV OF TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202510163399.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-02-14
Publication Date
2025-05-16

AI Technical Summary

Technical Problem

In the prior art, the production of L-2-aminobutyric acid by biofermentation method has problems such as low biomass, low titer and difficulty in industrial production.

Method used

By constructing a genetically engineered strain, the specific steps include knocking out mgsA, proP, proVWX, fadR, pflB, pfkB, pykF, amn genes, and overexpressing the carD, atpA, nadD, rpoS genes to optimize the metabolic pathway and energy supply of the strain.

Benefits of technology

The titer of L-2-aminobutyric acid was significantly improved, from 0.21 g/L to 2.35 g/L, and the growth adaptability and tolerance of the strain were improved, with OD600 increasing by 33.4% to 7.03.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120005785A_ABST
    Figure CN120005785A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of microbial metabolism engineering, in particular to a genetically engineered bacterium for efficiently producing L-2-aminobutyric acid as well as a construction method and application of the genetically engineered bacterium. According to the invention, Escherichia coli 19031-4 is used as a chassis strain, and the whole metabolic pathway is globally regulated and controlled through knockout and overexpression of a specific gene, so that the growth adaptability and tolerance of the strain are improved, and the titer of synthesizing L-2-aminobutyric acid is integrally improved. According to the invention, through multi-module regulation and control, the growth defect of a chassis strain is repaired by using transcriptional regulation and control factors, so that the waste of carbon flow is weakened, the positive influence of cofactors and energy supply on main pathway metabolism is strengthened, and the titer of L-2-aminobutyric acid is greatly improved while OD600 improvement is realized. A series of experiments prove that the genetically engineered bacterium disclosed by the invention can be used as a genetically engineered bacterium for multi-module regulation to promote high yield of L-2-aminobutyric acid in escherichia coli, and a thought is provided for production of more non-natural amino acids.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of microbial metabolic engineering, and in particular to a genetically engineered bacterium capable of efficiently producing non-natural chiral α-amino acids. Background Art

[0002] L-2-Aminobutyric acid (L-2-Aminobutyric acid) is an important non-natural chiral α-amino acid, which is widely used in the chemical industry and the pharmaceutical field, and it is also a key intermediate in the preparation process of high-demand drugs. Therefore, as an important precursor substance, L-2-aminobutyric acid is widely used in feed, medicine, and chemical industry. At present, the synthesis method of L-2-aminobutyric acid can be divided into chemical method and biological method. Among them, the reaction conditions of chemical synthesis of L-2-aminobutyric acid are relatively complex, it is easy to produce by-products, and it is easy to cause environmental pollution. Therefore, in recent years, the biological synthesis of L-2-aminobutyric acid has received more attention. Among the existing L-2-aminobutyric acid synthesis methods, the production of L-2-aminobutyric acid by biological fermentation has the characteristics of cheap substrate, easy separation, and low toxicity.

[0003] However, there are still some defects in the current production of L-2-aminobutyric acid using biological methods, such as unstable fermentation process, low biomass, low titer and other thorny problems. Therefore, constructing and optimizing a high-yield L-2-aminobutyric acid Escherichia coli strain is still one of the important goals of current research. For example, the recombinant bacteria for producing L-2-aminobutyric acid and its preparation method disclosed in patent 201510208576.1, the recombinant bacteria disclosed in the patent simultaneously overexpress threonine deaminase, transaminase and glutamate dehydrogenase, improve the yield and substrate conversion rate of L-2-aminobutyric acid, effectively reduce the accumulation of by-products, and simplify the production process. However, the raw material cost required for this technical solution is high, and the synthesized L-2-aminobutyric acid has a low titer, which limits its industrial practice. Summary of the invention

[0004] The present invention aims to overcome the defects of low biomass, low titer and difficulty in industrial production of L-2-aminobutyric acid in L-2-aminobutyric acid production strains, and provides a genetically engineered bacterium for efficiently producing L-2-aminobutyric acid and a construction method and application thereof to overcome the above defects.

[0005] In order to achieve the purpose of the above invention, the present invention is implemented by the following technical solutions: In the first aspect, the present invention discloses a genetically engineered bacterium for efficiently producing L-2-aminobutyric acid. The genetically engineered bacterium is based on Chapan bacteria 19031-4, with the mgsA, proP, proVWX, fadR, pflB, pfkB, pykF, and amn genes knocked out, and the carD, atpA, nadD, and rpoS genes overexpressed.

[0006] Based on the L-2-aminobutyric acid production strain 19031-4 that has been constructed in the previous laboratory, this patent has transformed Escherichia coli through metabolic engineering to construct a L-2-aminobutyric acid production strain with better performance. The strain 19031-4 is disclosed in patent 202210091140.9. The engineered bacteria knocks out the competitive genes related to the glucose PTS pathway of Escherichia coli to reduce the consumption of phosphoenolpyruvate, and improves the expression of the main synthesis pathway genes by overexpressing the genes ilvA and leuDH. The strain 19031-4 can achieve a yield of 10.86g / L without the addition of an inducer. However, in practice, it was found that the strain 19031-4 produced a large number of by-products during fermentation, and the culture conditions were relatively strict, which was not conducive to industrial production.

[0007] Therefore, the present invention repairs the growth defect of the L-2-aminobutyric acid chassis strain by (1) eliminating the byproduct lactic acid and introducing the gene carD encoding RNA polymerase from Mycobacterium neogoldensis, so that the strain exhibits a higher transcription level through the regulation of heterologous transcription factors; (2) knocking out the proP and proVWX genes respectively, and modifying the osmotic protectant betaine transporter to enhance the strain's ability to resist osmotic pressure stress; (3) promoting fatty acid degradation, knocking out the fadR gene, and increasing the supply of precursor acetyl CoA; (4) eliminating the byproduct formic acid and overexpressing the gene atpA encoding ATP synthase to enhance energy supply; (5) overexpressing the gene encoding nicotinic acid mononucleotide adenylate transferase The gene nadD was used to further increase the redox flux. (6) The genes encoding key enzymes in glycolysis and gluconeogenesis, pfkB and pykF, were deleted to redirect the sugar metabolism flux to the pentose phosphate pathway to reduce the production of acetate, reduce carbon source consumption, and allow more carbon flow to the L-2-aminobutyric acid synthesis pathway. (7) The gene encoding AMP nucleosidase amn was knocked out and the σ transcription factor gene encoding RNA polymerase rpoS was overexpressed to reduce the catabolism of ATP in the strain. Although the reduction of ADP and AMP may lead to a reduction in nucleotides, the intervention of the RpoS system can regulate the RNA level in E. coli and effectively manage the RNA activity in E. coli, thereby reducing OD. 600 The combination of the two globally regulated the growth and production of L-2-aminobutyric acid, producing a significant positive impact.

[0008] Furthermore, the nucleotide sequences of the mgsA, proP, proVWX, fadR, pflB, pfkB, pykF, and amn genes are shown in SEQ ID NOs. 1 to 8, respectively.

[0009] Furthermore, the nucleotide sequences of the carD, atpA, nadD, and rpoS genes, and the Ptrc-carD, Ptrc-atpA, Ptrc-nadD, and Ptrc-rpoS genes regulated by the trc promoter are shown in SEQ ID NOs. 9 to 12, respectively.

[0010] In a second aspect, the present invention discloses a method for constructing the above-mentioned engineered bacteria, comprising the following steps: S1, knocking out the gene mgsA and overexpressing the gene carD in the genome of the chassis bacteria 19031-4 to obtain the engineered bacteria 19031-4derivative, mgsA::Ptrc-carD, recorded as the engineered bacteria ABAT1; S2, knocking out the gene proP in the genome of the engineered bacterium ABAT1 to obtain an engineered bacterium ABAT1 derivative, ΔproP, which is recorded as the engineered bacterium ABAT2; S3, knocking out the gene proVWX in the genome of the engineered bacterium ABAT2 to obtain the engineered bacterium ABAT2 derivative, ΔproVWX, recorded as the engineered bacterium ABAT3; S4, knocking out the gene fadR in the engineered bacteria ABAT3 to obtain the engineered bacteria ABAT3 derivative, ΔfadR, recorded as the engineered bacteria ABAT4; S5, knocking out the gene pflB in the engineered bacteria ABAT4 and overexpressing the gene atpA, obtaining the engineered bacteria ABAT4derivative, pflB::Ptrc-atpA, recorded as the engineered bacteria ABAT5; S6, overexpressing the nicotinic acid mononucleotide adenylate transferase encoding gene nadD in the genome of the engineered bacterium ABAT5 to obtain the engineered bacterium ABAT5 derivative, PnadD::Ptrc, recorded as the engineered bacterium ABAT6; S7, knocking out the gene pfkB in the genome of the engineered bacterium ABAT6 to obtain the engineered bacterium ABAT6 derivative, ΔpfkB, recorded as the engineered bacterium ABAT7; S8, knocking out the gene pykF in the genome of the engineered bacterium ABAT7 to obtain an engineered bacterium ABAT7 derivative, ΔpykF, which is recorded as the engineered bacterium ABAT8; S9. Knock out the amn gene and overexpress the rpoS gene in the genome of the engineered bacterium ABAT8 to obtain the engineered bacterium ABAT8derivative, amn::Ptrc-rpoS, recorded as the engineered bacterium ABAT9, which is the genetically engineered bacterium with high production of L-2-aminobutyric acid.

[0011] Furthermore, in the above steps, the method for knocking out genes is CRISPR-Cas9 gene editing.

[0012] Furthermore, the knockout vectors used to knock out genes are pCas9 and pTarget, and their nucleotide sequences are shown in SEQ ID NOs. 13 to 14, respectively.

[0013] In a third aspect, the present invention further discloses an application of the above-mentioned genetically engineered bacteria for efficiently producing L-2-aminobutyric acid in the preparation of L-2-aminobutyric acid by microbial fermentation.

[0014] In a fourth aspect, the present invention further discloses a method for preparing L-2-aminobutyric acid, characterized in that it comprises the following steps: S1. inoculating the genetically engineered bacteria capable of efficiently producing L-2-aminobutyric acid into a fermentation medium; S2, adding inducer and carrying out fermentation culture; S3. After the fermentation is completed, the fermentation liquid is taken and the supernatant is separated to obtain L-2-aminobutyric acid.

[0015] Furthermore, in the preparation method of L-2-aminobutyric acid, in step S1, the genetically engineered bacteria are first cultured in LB medium overnight, and then inoculated into a fermentation medium for culture.

[0016] Therefore, the present invention has the following beneficial effects: (1) The present invention selected a strain 19031-4 that had been constructed in the laboratory in the early stage as the chassis strain, and used CRISPR-Cas9 gene editing to heterologously introduce the RNA polymerase encoding gene carD in the new golden Mycobacterium, so that the growth defect of the strain L-2-aminobutyric acid was repaired; (2) The present invention enhances the strain's ability to resist osmotic stress by modifying the main and secondary transport proteins of the osmotic protectant betaine, so that the titer of L-2-aminobutyric acid reaches 0.82 g / L, and the OD 600 Reached 5.95; (3) The present invention promotes fatty acid degradation and increases acetyl-CoA supply by knocking out fadR, and the titer of L-2-aminobutyric acid reaches 1.12 g / L, OD 600 Reached 5.27; (4) The present invention enhances the supply of cofactors and energy while eliminating the byproduct formic acid to enhance the metabolic driving force required in the synthesis pathway. By deleting the genes encoding key enzymes in glycolysis and gluconeogenesis, pfkB and pykF, the sugar metabolism flux is redirected to the pentose phosphate pathway to reduce the production of acetate, reduce carbon source consumption, and allow more carbon flow to flow to the L-2-aminobutyric acid synthesis pathway; (5) The present invention knocks out the AMP nucleosidase encoding gene amn and overexpresses the RNA polymerase encoding σ transcription factor gene rpoS to globally regulate the entire metabolic pathway, improve the growth adaptability and tolerance of the strain, and improve the titer of L-2-aminobutyric acid as a whole, so that the titer of L-2-aminobutyric acid is further increased to 2.35 g / L, and the OD 600 Increased by 33.4% to 7.03. (6) The present invention uses multi-module regulation and transcriptional regulatory factors to repair the growth defects of the chassis strain, which weakens the waste of carbon flow while strengthening the positive effects of cofactors and energy supply on the main pathway metabolism, achieving OD 600 At the same time, the potency of L-2-aminobutyric acid was greatly improved. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Schematic diagram of the L-2-aminobutyric acid metabolic pathway and key sites.

[0018] Figure 2 OD of ABAT1 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0019] Figure 3 OD of ABAT2 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0020] Figure 4 OD of ABAT3 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0021] Figure 5 OD of ABAT4 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0022] Figure 6 OD of ABAT5 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0023] Figure 7 OD of ABAT6 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0024] Figure 8OD of ABAT7 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0025] Fig. 9 OD of ABAT8 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0026] Fig.10 OD of ABAT9 600 And schematic diagram of the changes in L-2-aminobutyric acid titer.

[0027] Fig.11 The OD value of the biomass of ABAT9 in the 5L fermenter fed-batch fermentation was 600 And L-2-aminobutyric acid concentration curve. DETAILED DESCRIPTION

[0028] The present invention is further described below in conjunction with specific embodiments. Those of ordinary skill in the art will be able to implement the present invention based on these descriptions. In addition, the embodiments of the present invention involved in the following description are generally only embodiments of a part of the present invention, rather than all embodiments. Therefore, all other embodiments obtained by those of ordinary skill in the art without creative work based on the embodiments in the present invention should belong to the scope of protection of the present invention. The experimental methods in the following embodiments are conventional methods unless otherwise specified. The test materials used in the following embodiments are purchased from conventional reagent stores unless otherwise specified. The quantitative experiments in the following embodiments are all set up for three repeated experiments, and the results are averaged.

[0029] The parent strain E. coli W3110 of the present invention is from the Coli Genetic Stock Center of Yale University, with a deposit date of August 5, 1975, a deposit number of CGSC#4474, and has been disclosed in patents US2009 / 0298135A1 and US2010 / 0248311A1. In the following specific embodiments, the final concentration of kanamycin in the culture medium is 0.05 mg / L, and the final concentration of spectinomycin in the culture medium is 0.05 mg / L.

[0030] The genes and corresponding pathways involved in gene editing are shown in Table 1: Table 1: Genes and corresponding pathways involved in gene editing

[0031] The primer sequences used are shown in Table 2: Table 2: Primer sequences

[0032] The HPLC determination method of L-2-aminobutyric acid content in the following specific implementation manner is as follows: Chromatographic conditions: C18 column (250×4.6 mm, particle size 5 μm, Agilent Technologies Co., Santa Clara, CA, USA), detection wavelength: 360 nm, column temperature: 30°C; Sample treatment: Take 1 mL of fermentation broth, centrifuge at room temperature, 12000 rpm for 1 min, dilute the supernatant appropriately to keep the L-2-aminobutyric acid content between 0.1 g / L and 3.0 g / L; Mobile phase: acetonitrile / water / sodium dihydrogen phosphite dodecahydrate: (300ml / 700ml / 5.012g); Data collection time: 10 minutes.

[0033] Example 1: Construction and shake flask fermentation of ABAT1 (19031-4 derivative, mgsA::Ptrc-carD) 19031-4 (E. coli W3110 derivative, ΔlacI, thrA (C1034T) ,lysC (C1055T) , Ptrc-thrABC::Ptac, ΔlysA, ΔmetA, Δtdh, ΔiclR, Pppc::PTrc, ΔilvIH::Gap-ilvA*-PBS-leuDH) was used as the starting strain, and the CRISPR-Cas9-mediated gene editing technology was used to replace the original methylglyoxal synthase encoding gene mgsA (nucleotide sequence shown in SEQ IQNO.1) on the genome of the starting strain with the carD gene (nucleotide sequence shown in SEQ IQNO.9) encoding the RNA polymerase in the new golden Mycobacterium regulated by the trc promoter derived from pTrc99A through a gene knockout method. While reducing lactic acid synthesis, the strain showed a higher transcription level through the regulation of heterologous transcription factors, thereby restoring the growth rate of the L-2-aminobutyric acid strain. (1) Construction of pTarget-mgsA plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and mgsA-sgRNA-F / mgsA-sgRNA-R were used as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The plasmid was screened on a spectinomycin plate and sequenced to verify the correct pTarget-mgsA plasmid, which was used for the subsequent connection of mgsA-up, mgsA-down and Donor DNA. (2) Construction of pTarget-mgsA::Trc-carD plasmid: Using the E. coli W3110 genome as a template, mgsA-up-F and mgsA-up-R were used as primers to amplify mgsA-up, mgsA-down-F and mgsA-down-R were used as primers to amplify mgsA-down, and pTarget-mgsA plasmid was amplified using PT-line-F and PT-line-R as primers to obtain pTarget-line-mgsA. Then, using the E. coli W3110 genome as a template, carD-F / carD-R were used as primers to amplify the carD gene fragment with the promoter Ptrc, and the DNA fragment was recovered using a Clean up kit; according to pTarget-line-mgsA, Trc-carD, mgsA-up and mgsA-down were connected together according to the instruction manual of (One step clone kit, Vazyme Biotech, Nanjing, China) and the pTarget-mgsA::Trc-carD plasmid was obtained by sequencing verification. (3) Introduce pCas plasmid (Addgene Plasmid #62225) into 19031-4 and transfer the single clone to Incubate overnight at 30°C in a LB tube containing 0.05 mg / L kanamycin; then inoculate into a 250 mL shake flask containing 50 mL LB medium at a volume concentration of 1%, add 500 μl 1 mol / L L-arabinose, and culture at 150 rpm and 30°C until OD 600 0.4~0.6; 4000rpm, 4℃ centrifugation for 10min to collect cells and prepare electroporation competent cells. For detailed process, see (Molecular Cloning: A Laboratory Manual, 3ed Edition, 99-102). (4) Take 200 ng of pTarget-mgsA:::Ptrc-carD plasmid and mix it with 100 μl of electroporated competent cells, transfer it into a pre-cooled 2 mm electroporation cup, place it on ice for about 1 min, and use an electroporator (MicroPluser TM , BIO-RAD) for electroporation transformation. After the electroporation is completed, 1 mL of LB medium is immediately added and gently aspirated, and the plate is transferred to a 1.5 mL centrifuge tube. After resuscitation at 30°C for 2-3 hours, it is coated with LB plates containing 0.05 mg / L kanamycin and 0.05 mg / L spectinomycin, and inverted culture is carried out at 37°C for 12-16 hours. Colony PCR verification is performed using mgsA-VF and mgsA-VR as primers. If a fragment of about 1500 bp can be successfully cloned, it proves to be a 19031-4derivative, mgsA::Ptrc-carD positive colony. (5) Plasmid elimination: Pick a single positive colony and inoculate it into an LB test tube containing 1 mM IPTG and 0.05 mg / L kanamycin, culture it at 30°C overnight, and streak the bacterial liquid onto an LB plate containing 0.05 mg / L kanamycin the next day. Culture it at 30°C for 24 h, pick a single colony and streak it onto an LB plate containing 0.05 mg / L spectinomycin. If the single colony cannot be successfully eliminated on the LB plate containing 0.05 mg / L spectinomycin, pick pTarget-mgsA::Ptrc-carD plasmid. A single colony with successfully eliminated A::Ptrc-carD plasmid was placed in an LB test tube and cultured at 37°C overnight. The next day, the bacterial liquid was streaked on an LB plate and cultured at 37°C for 12 hours. A single colony was picked and streaked on an LB plate containing 0.05 mg / L kanamycin. The pCas plasmid of the single colony that could not be successfully eliminated on the LB plate containing 0.05 mg / L kanamycin was finally obtained, and the plasmid-free 19031-4 derivative, mgsA::Ptrc-carD, was obtained. (6) 19031-4 derivative, mgsA::Ptrc-carD, and 19031-4 as the control group were inoculated into 10 mL of LB medium and cultured at 37°C and 200 rpm as pre-cultures; after 8-12 hours, 1 mL of the pre-culture was inoculated into a 500 mL shake flask containing 30 mL of TYM medium, and then fermented in a constant temperature shaker at 37°C and 200 rpm for 48 hours; after the fermentation, 1 mL of the fermentation broth was taken to measure the OD 600 , take 1 mL of fermentation broth, centrifuge at 12000 rpm at room temperature for 5 min, and dilute the fermentation supernatant 10 times.

[0034] The diluted fermentation supernatant was tested according to the above-mentioned HPLC method for the content of L-2-aminobutyric acid. 600 And the L-2-aminobutyric acid content in the fermentation broth supernatant Figure 2 As shown in the figure, knocking out the mgsA gene and introducing the heterologous carD gene in the 19031-4 genome has a very significant promoting effect on cell growth. 600 It increased from 1.12 (19031-4 had extremely weak growth ability) to 4.42, and the L-2-aminobutyric acid titer increased from 0.21 g / L to 0.63 g / L, which shows that the knockout of mgsA reduced the consumption of carbon source and promoted the flow of carbon source to the L-2-aminobutyric acid synthesis pathway. In addition, the introduction of carD gene significantly improved cell growth, and the increase in bacterial mass greatly promoted the synthesis of L-2-aminobutyric acid.

[0035] In the above embodiment, the specific composition of LB medium is: 10g / L peptone, 5g / L yeast extract, 5g / L NaCl, the solvent is deionized water, and the pH value is natural. The specific composition of TYM medium is: glucose 20g / L, MgSO4·7H2O2g / L, (NH)2SO4 14g / L, potassium dihydrogen phosphate 4.0g / L, yeast extract 6g / L, tryptone 10g / L, anhydrous citric acid 4g / L, ammonium sulfate 14g / L, betaine 1g / L, L-lysine 0.164g / L, L-methionine 0.149g / L, 5ml / L trace metal element solution, and the solvent is deionized water. The composition of the metal salt ion solution is: FeSO4·7H2O 10g / L, CaCl2 1.35g / L, ZnSO4·7H2O 2.25g / L, MnSO4·4H2O 0.5g / L, CuSO4·5H2O 1g / L, (NH4)6Mo7O 24 ·4H2O 0.106g / L, Na2B4 O7·10H2O 0.23g / L, 35% HCl 10mL / L, the solvent is water.

[0036] Example 2: Construction and shake flask fermentation of ABAT2 (ABAT1 derivative, ΔproP): Taking ABAT1 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to knock out the gene proP (nucleotide sequence as shown in SEQ IQ NO.2) encoding the main betaine transporter in Escherichia coli through the gene knockout method, further enhancing the strain's ability to resist osmotic stress. (1) Construction of pT-proP plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and proP-sgRNA-F / proP-sgRNA-R as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The product was screened on a spectral plate and sequenced to verify the correct pTarget-proP plasmid for subsequent proP-up / proP-down ligation. (2) Construction of pTarget-proP plasmid: Using the E. coli W3110 genome as a template, proP-up-F and proP-up-R were used as primers to amplify proP-up, proP-down-F and proP-down-R were used as primers to amplify proP-down, and pTarget-proP plasmid was amplified using PT-line-F and PT-line-R as primers to obtain pTarget-line-proP, and the Cleanup kit was used to recover the DNA fragments; (One step clone kit, Vazyme Biotech, Nanjing, China) instructions were used to connect pTarget-line-proP, proP-up and proP-down together, and the pTarget-proP plasmid was obtained by sequencing verification. (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the ABAT1 competent cell obtained in Example 1 (5). The preparation method of ABAT1 competent cell was the same as that of Example 1 (3). (4) ABAT2 positive colonies were constructed using the same method as in Example 1 (4). (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free ABAT2. (6) The constructed ABAT2 engineered strain was used as a control group with the ABAT1 constructed in Example 1, and shake flask tests and detection were performed according to the method of Example 1 (6).

[0037] OD 600 And the L-2-aminobutyric acid content in the fermentation broth supernatant Figure 3 As shown in the figure, knocking out proP in the ABAT1 genome, cell OD 600 The protein content of proP increased from 4.42 to 5.48, while the titer of L-2-aminobutyric acid increased from 0.63 g / L to 0.71 g / L. The increase in cell OD value further proved that the knockout of proP enhanced the strain's ability to adapt to the environment, improved cell robustness, and was beneficial to the synthesis of L-2-aminobutyric acid.

[0038] Example 3: Construction and shake flask fermentation of ABAT3 (ABAT2 derivative, ΔproVWX) Using ABAT2 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to knock out the gene proVWX (nucleotide sequence as shown in SEQ IQ NO.3) encoding the betaine minor transporter in Escherichia coli through a gene knockout method, thereby further enhancing the strain's ability to resist osmotic stress. (1) Construction of pT-proVWX plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and proVWX-sgRNA-F / proVWX-sgRNA-R as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The product was screened on a spectinomycin plate and sequenced to obtain the correct pTarget-proVWX plasmid for subsequent ligation of proVWX-up / proVWX-down. (2) Construction of pTarget-proVWX plasmid: Using the E. coli W3110 genome as a template, proVWX-up-F and proVWX-up-R were used as primers to amplify proVWX-up, and proVWX-down-F and proVWX-down-R were used as primers to amplify proVWX-down. The pTarget-proVWX plasmid was amplified using PT-line-F and PT-line-R as primers to obtain pTarget-line-proVWX. The DNA fragment was recovered using a Clean up kit; pTarget-line-proVWX, proVWX-up and proVWX-down were connected together according to the instruction manual of the kit (One step cloning kit, Vazyme Biotech, Nanjing, China), and the pTarget-proVWX plasmid was obtained by sequencing verification. (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the ABAT2 competent cells obtained in Example 2 (5). The preparation method of ABAT2 competent cells was the same as that of Example 1 (3). (4) ABAT3 positive colonies were constructed using the same method as in Example 1 (4). (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free ABAT3. (6) The constructed ABAT3 engineered strain was used as a control group with the ABAT2 constructed in Example 2, and shake flask tests and detection were performed according to the method of Example 1 (6).

[0039] OD600 The accumulation of L-2-aminobutyric acid in the fermentation supernatant was as follows: Figure 4 As shown in the figure, knocking out proVWX in the ABAT1 genome will increase the cell OD 600 The osmotic pressure increased from 5.48 to 5.95, while the L-2-aminobutyric acid titer increased from 0.71 g / L to 0.82 g / L, indicating that the knockout of proVWX may disturb the intracellular osmotic pressure, and the cells may increase the uptake and utilization of carbon sources, increasing the carbon source flowing to L-2-aminobutyric acid synthesis to maintain normal physiological activities. The osmotic pressure double deletion mutant seems to be more suitable for increasing the titer of L-2-aminobutyric acid.

[0040] Example 4: Construction and shake flask fermentation of ABAT4 (ABAT3 derivative, ΔfadR) Using ABAT3 as the starting strain, the CRISPR-Cas9-mediated gene editing technology was used to knock out the gene fadR encoding the regulatory protein in fatty acid metabolism in the genome of the engineered bacterium ABAT3, thereby promoting fatty acid degradation and increasing the supply of acetyl-CoA, thereby obtaining the engineered bacterium ABAT3derivative, ΔfadR, which was recorded as the engineered bacterium ABAT4. (1) Construction of pT-fadR plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and fadR-sgRNA-F / fadR-sgRNA-R as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The product was screened on a spectinomycin plate and sequenced to obtain the correct pTarget-fadR plasmid for subsequent fadR-up / fadR-down ligation. (2) Construction of pTarget-fadR plasmid: Using the E. coli W3110 genome as a template, fadR-up was amplified using primers fadR-up-F and fadR-up-R, fadR-down was amplified using primers fadR-down-F and fadR-down-R, and pTarget-fadR plasmid was amplified using primers PT-line-F and PT-line-R to obtain pTarget-line-fadR. The DNA fragments were recovered using a Cleanup kit; (One step clone kit, Vazyme Biotech, Nanjing, China) instructions were used to connect pTarget-line-fadR, fadR-up and fadR-down together, and the pTarget-fadR plasmid was obtained by sequencing verification. (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the ABAT3 competent cell obtained in Example 3 (5). The preparation method of ABAT3 competent cell was the same as that of Example 1 (3). (4) ABAT4 positive colonies were constructed using the same method as in Example 1 (4). (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free ABAT4. (6) The constructed ABAT4 engineered strain was used as a control group with the ABAT3 constructed in Example 3, and shake flask tests and detection were performed according to the method of Example 1 (6).

[0041] OD 600 And the L-2-aminobutyric acid content in the fermentation broth supernatant Figure 5 As shown in the figure, knocking out fadR in the ABAT3 genome will increase the cell OD 600 It decreased from 5.95 to 5.27, while the L-2-aminobutyric acid titer increased from 0.82 g / L to 1.12 g / L, indicating that the knockout of fadR slightly inhibited cell growth, which may be due to the lack of fatty acids. However, it promoted the degradation of fatty acids and helped accumulate acetyl-CoA, a precursor substance, and promoted the accumulation of L-2-aminobutyric acid, which was more conducive to subsequent transformation than ABAT3.

[0042] Example 5: Construction and shake flask fermentation of ABAT5 (ABAT4 derivative, pflB::Ptrc-atpA) Using ABAT4 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to replace the original pflB gene (nucleotide sequence as shown in SEQ IQ NO.5) on the genome of the starting strain with the atpA gene regulated by the trc promoter derived from pTrc99A (nucleotide sequence as shown in SEQ IQ NO.10) through the gene knock-in method, thereby eliminating formic acid by-products and enhancing energy supply. (1) Construction of pTarget-pflB plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and pflB-sgRNA-F / pflB-sgRNA-R were used as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The plasmid was screened on a spectinomycin plate and sequenced to verify the correct pTarget-pflB plasmid, which was used for subsequent ligation of pflB-up, pflB-down and Trc-atpA. (2) Construction of pTarget-pflB::Trc-atpA plasmid: Using the E. coli W3110 genome as a template, pflB-up-F and pflB-up-R were used as primers to amplify pflB-up, pflB-down-F and pflB-down-R were used as primers to amplify pflB-down, and pTarget-pflB plasmid was amplified using PT-line-F and PT-line-R as primers to obtain pTarget-line-pflB. Then, using the E. coli W3110 genome as a template, atpA-F and atpA-R were used as primers to amplify the atpA gene fragment with the promoter Ptrc, and the DNA fragment was recovered using a Clean up kit; according to pTarget-line-pflB, Ptrc-atpA, pflB-up and pflB-down were connected together according to the instruction manual of (One step clone kit, Vazyme Biotech, Nanjing, China) and the pTarget-pflB::Trc-atpA plasmid was obtained by sequencing verification. (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the ABAT4 competent cell obtained in Example 4 (5). The preparation method of ABAT4 competent cell was the same as that of Example 1 (3). (4) ABAT5 positive colonies were constructed using the same method as in Example 1 (4). (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free ABAT5. (6) The constructed ABAT5 engineered strain was used as a control group with ABAT4, and shake flask tests and detection were performed according to the method of Example 1 (6).

[0043] OD 600 And the L-2-aminobutyric acid content in the fermentation broth supernatant Figure 6 As shown in the figure, after knocking out the formate C-acetyltransferase encoding gene pflB and overexpressing the atpA gene in the ABAT4 genome, the cell OD600 It increased from 5.27 to 6.57, while the L-2-aminobutyric acid titer increased from 1.12g / L to 1.25g / L. The elimination of by-product miscellaneous acids and the enhancement of energy supply further drove the carbon metabolic flow. The two worked together to significantly increase the L-2-aminobutyric acid titer. Subsequent pathway modification will further optimize this.

[0044] Example 6: Construction and shake flask fermentation of ABAT6 (ABAT5 derivative, PnadD::Ptrc) Using ABAT5 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to replace the original nadD gene on the genome of the starting strain by the gene knock-in method, which was regulated by the trc promoter derived from pTrc99A (nucleotide sequence as shown in SEQ IQ NO.11) to increase the redox flux. (1) Construction of pTarget-PnadD plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and PnadD-sgRNA-F / PnadD-sgRNA-R were used as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The plasmid was screened on a spectinomycin plate and sequenced to verify the correct pTarget-PnadD plasmid, which was used for the subsequent connection of PnadD-up, PnadD-down and Donor DNA. (2) Construction of pTD-PnadD plasmid: Using the E. coli W3110 genome as a template, PnadD-up-F and PnadD-up-R were used as primers to amplify PnadD-up, PnadD-down-F and PnadD-down-R were used as primers to amplify PnadD-down, and pTarget-PnadD plasmid was amplified using PT-line-F and PT-line-R as primers to obtain pTarget-line-PnadD. Then, using the E. coli W3110 genome as a template, pT-PnadD-F / pT-PnadD-R were used as primers to amplify the nadD gene fragment with the promoter Ptrc, and the DNA fragment was recovered using a Clean up kit; according to pTarget-X-PnadD, Ptrc-nadD, PnadD-up and PnadD-down were connected together according to the instruction manual of (One stepclone kit, Vazyme Biotech, Nanjing, China) and the PnadD::Ptrc plasmid was obtained by sequencing verification. (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the ABAT5 competent cell obtained in Example 5 (5). The preparation method of ABAT5 competent cell was the same as that of Example 1 (3). (4) ABAT6 positive colonies were constructed using the same method as in Example 1 (4). (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free ABAT6. (6) The constructed ABAT6 engineered strain was used as a control group with the ABAT5 constructed in Example 5, and shake flask tests and detection were performed according to the method of Example 1 (6).

[0045] OD 600 And the L-2-aminobutyric acid content in the fermentation broth supernatant Figure 7 As shown in the figure, after overexpression of nadD gene in ABAT5 genome, cell OD 600 From 6.57 to 6.72, the titer of L-2-aminobutyric acid increased from 1.25g / L to 1.31g / L. Analysis shows that the key enzyme leucine dehydrogenase needs to consume NAD + After the energy is enhanced, the supply of required cofactors is further increased, which has a significant impact on the action of key enzymes. In addition, the activity of leucine dehydrogenase can relieve the toxicity caused by the accumulation of the intermediate product 2-ketobutyric acid to the greatest extent, and has a positive effect on cell growth and the synthesis of L-2-aminobutyric acid products.

[0046] Example 7: Construction and shake flask fermentation of ABAT7 (ABAT6 derivative, ΔpfkB) Using ABAT5 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to knock out the 6-phosphofructokinase II encoding gene pfkB (nucleotide sequence as shown in SEQ IQ NO.7) through a gene knockout method to balance the metabolic flux of the EMP pathway and the TCA cycle and reduce the carbon flux overflow of acetate. (1) Construction of pTarget-pfkB plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and pfk B-sgRNA-F / pfkB-sgRNA-R were used as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The plasmid was screened on a spectinomycin plate and sequenced to verify the correct pTarget-pfkB plasmid for subsequent ligation of pfkB-up / pfkB-down. (2) Construction of pTarget-pfkB plasmid: Using the E. coli W3110 genome as a template, pfkB-up-F and pfkB-up-R were used as primers to amplify pfkB-up, pfkB-down-F and pfkB-down-R were used as primers to amplify pfkB-down, and pT-pfkB plasmid was amplified using PT-line-F and PT-line-R as primers to obtain pTarget-line-pfkB. The DNA fragments were recovered using a Clean up kit; pTarget t-line-pfkB, pfkB-up and pfkB-down were connected together according to the instruction manual of (One step cloning kit, Vazyme Biotech, Nanjing, China) and the pTarget-pfkB plasmid was obtained by sequencing verification. (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the ABAT6 competent cell obtained in Example 6 (5). The preparation method of ABAT6 competent cell was the same as that of Example 1 (3). (4) ABAT7 positive colonies were constructed using the same method as in Example 1 (4). (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free ABAT7. (6) The constructed ABAT7 engineered strain was used as a control group with the ABAT6 constructed in Example 7, and shake flask tests and detection were performed according to the method of Example 1 (6).

[0047] OD 600 And the L-2-aminobutyric acid content in the fermentation broth supernatant Figure 8 As shown in the figure, after the pfkB gene was knocked out in the ABAT6 genome, the cell OD 600 From 6.72 to 6.41, however, the titer of L-2-aminobutyric acid increased from 1.31g / L to 1.47g / L. After the pfkB gene was deleted, the driving force of the EMP pathway was weakened, affecting cell growth, but the carbon flux was more effectively directed to the L-2-aminobutyric acid synthesis pathway, producing more L-2-aminobutyric acid. And through the fermentation broth detection, it can be seen that the acetic acid content is significantly reduced, which also reflects that the knockout of this gene saves carbon metabolism from flowing to organic acid byproducts.

[0048] Example 8: Construction and shake flask fermentation of ABAT8 (ABAT7 derivative, ΔpykF) Using ABAT7 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to knock out the pyruvate kinase I encoding gene pykF in the ABAT7 genome to obtain the engineered bacterium ABAT7derivative, ΔpykF. (1) Construction of pTarget-pykF plasmid: pTarget F plasmid (Addgene Plasmid #62226) was used as a template and pykF-sgRNA-F / pykF-sgRNA-R as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 h and then transformed into E. coli DH5α. The plasmid was screened on a spectinomycin plate and sequenced to verify the correct pTarget-pykF plasmid for subsequent ligation of pykF-up / pykF-down. (2) Construction of pTarget-pykF plasmid: Using the E. coli W3110 genome as a template, pykF-up and pykF-up-R were used as primers to amplify pykF-up, pykF-down-F and pykF-down-R were used as primers to amplify pykF-down, and pT-pykF plasmid was amplified using PT-line-F and PT-line-R as primers to obtain pTarget-line-pykF, and the Clean up kit was used to recover the DNA fragments; (One step clone kit, Vazyme Biotech, Nanjing, China) instructions were used to connect pTarget-line-pykF, pykF-up and pykF-down together, and the pTarget-pykF plasmid was obtained by sequencing verification. (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the ABAT7 competent cell obtained in Example 7 (5). The preparation method of ABAT7 competent cell was the same as that of Example 1 (3). (4) ABAT8 positive colonies were constructed using the same method as in Example 1 (4). (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free ABAT8. (6) The constructed ABAT8 engineered strain was used as a control group with the ABAT7 constructed in Example 7, and shake flask tests and detection were performed according to the method of Example 2 (6).

[0049] OD 600 And the L-2-aminobutyric acid content in the fermentation broth supernatant Fig. 9As shown in the figure, after knocking out the pykF gene in the ABAT7 genome, the cell OD 600 The pykF knockout weakened the carbon flux from PEP to PYR and redirected the carbon flow to the pentose phosphate pathway, which on the one hand accumulated the precursor PEP and on the other hand reduced the production of organic acids. The results also showed that weakening the conversion of PEP to PYR can increase the titer of L-2-aminobutyric acid.

[0050] Example 9: Construction and shake flask fermentation of ABAT9 (ABAT8 derivative, amn::Ptrc-rpoS) Using ABAT8 as the starting strain, CRISPR-Cas9-mediated gene editing technology was used to replace the original amn gene (nucleotide sequence as shown in SEQ IQ NO.8) on the genome of the starting strain with the rpoS gene regulated by the trc promoter derived from pTrc99A (nucleotide sequence as shown in SEQ IQ NO.12) through a gene knockout method to obtain the engineered bacterium ABAT8 derivative, amn::Ptrc-rpoS. (1) Construction of pTarget-amn plasmid: pTarget F plasmid (Addgene Plasmid #62226) As a template, amn-sgRNA-F / amn-sgRNA-R were used as primers for PCR amplification. The PCR product was digested with Dpn I at 37°C for 3 hours, then transformed into E. coli DH5α, screened on a spectinomycin plate, and sequenced to obtain the correct pTa rget-amn plasmid for subsequent connection of amn-up, amn-down and Trc-rpoS. (2) Construction of pTarget-amn::Trc-rpoS plasmid: Using the E. coli W3110 genome as a template, amn-up-F and amn-up-R were used as primers to amplify amn-up, amn-down-F and amn-down-R were used as primers to amplify amn-down, and pTarget-amn plasmid was amplified using PT-line-F and PT-line-R as primers to obtain pTarget-line-amn. Then, using the E. coli W3110 genome as a template, rpoS-F / rpoS-R were used as primers to amplify the Trc-rpoS gene fragment with the promoter Ptrc, and the DNA fragment was recovered using a Clean up kit; according to pTarget-line-amn, Trc-rpoS, amn-up and amn-down were connected together according to the instruction manual of (One step cloning kit, Vazyme Biotech, Nanjing, China) and the pTarget-amn::Trc-rpoS plasmid was obtained by sequencing verification. (3) The pCas plasmid (Addgene Plasmid #62225) was introduced into the ABAT8 competent cell obtained in Example 8 (5). The preparation method of ABAT8 competent cell was the same as that of Example 1 (3). (4) ABAT9 positive colonies were constructed using the same method as in Example 1 (4). (5) Plasmid elimination: The implementation method is the same as Example 1 (5) to obtain plasmid-free ABAT9. (6) The constructed ABAT9 engineered strain was used as a control group with ABAT8, and shake flask tests and detection were performed according to the method of Example 1 (6).

[0051] OD 600 And the L-2-aminobutyric acid content in the fermentation broth supernatant Fig.10 As shown in the figure, after knocking out the amn gene and overexpressing the rpos gene in the ABAT8 genome, the cell OD 600 From 6.81 to 7.02, the titer of L-2-aminobutyric acid increased from 1.55 g / L to 2.05 g / L. The gene amn encodes AMP nucleosidase, and its knockout reduces the catabolism of ATP in strain ABAT8, but the reduction of ADP and AMP may lead to a reduction in nucleotides. However, through the intervention of the RpoS system, the RNA level in E. coli can be regulated and the RNA activity in E. coli can be effectively managed, so OD 600 The combination of the two globally regulates the growth and production of L-2-aminobutyric acid, producing a significant positive impact. At present, this strain has become a genetically engineered bacterium that promotes high production of L-2-aminobutyric acid in Escherichia coli through multi-module regulation.

[0052] Example 11: 5L tank fermentation test of engineered strain ABAT9 The optimal strain ABAT9 in the shake flask test was selected to carry out the L-2-aminobutyric acid production performance test in a 5L fermentor. The strain was streaked on an LB plate and cultured overnight in a 37°C incubator. A single colony was picked and inoculated into 10ml of LB medium and cultured at 37°C for 10h. Then 1ml of the test tube culture was inoculated into a 500ml Erlenmeyer flask containing 100ml of seed (LB liquid) medium and cultured at 200rpm in a 37°C incubator for 6-8h. 200ml of the seed culture was inoculated into a 5L fermentor (BIOTECH-5JG) containing 1.5L of fermentation medium. The feed medium was added by the fed batch method, and the fermentation cycle was 100-120h. During the fermentation process, the glucose concentration was controlled at 1-5g / L by feeding. The DO level during the fermentation process was controlled at about 20% by stirring-coupled dissolved oxygen (DO) mode, the stirring speed was controlled at 300–600 rpm, the aeration rate was controlled at 12 vvm, the culture temperature was controlled at 32 °C during the fermentation process, and the pH was adjusted to 7.4 ± 0.1 with 50% ammonia water. The fermentation medium composition is as follows: glucose 20 g / L, yeast powder 12 g / L, tryptone 12 g / L, L-methionine 0.149 g / L, potassium phosphate trihydrate 5.018 g / L, sodium chloride 3 g / L, L-lysine 0.164 g / L, magnesium sulfate heptahydrate 0.5 g / L, ammonium sulfate 2.5 g / L, ammonium ferric citrate 0.5 g / L, betaine 2 g / L, metal salt ion solution 5 ml / L, the solvent is deionized water, pH value 7.4; the metal salt ion solution composition is: FeSO4·7H2O 10 g / L, CaCl2 1.35 g / L, ZnSO4·7H2O 2.25 g / L, MnSO4·4H2O 0.5 g / L, CuSO4·5H2O 1 g / L, (NH4)6Mo7O 24 ·4H2O 0.106g / L, Na2 B4O7·10H2O 0.23g / L, 35% HCl 10mL / L, and the solvent is water; the feed medium consists of: 550g / L glucose, 12.5g / L potassium dihydrogen phosphate, 14g / L ammonium sulfate, 3g / L L-methionine, 4.4g / L L-lysine, and the solvent is water.

[0053] The fermentation curve during the fermentation process is shown in Fig.11 , including residual sugar, biomass (OD 600 ) and the changes in L-2-aminobutyric acid production over time. Fig.11It can be seen that the initial 20g / L glucose in the fermentation broth was basically consumed at 20h, the strain lacked nutrients and began to die, the dissolved oxygen value in the fermenter increased, and when the dissolved oxygen exceeded 20%, the automatic feeding was turned on. With the addition of the feed medium, the strain began to absorb nutrients and restore growth and production vitality. The dissolved oxygen value fluctuated around the set 20%, and the glucose concentration in the culture medium was maintained at a low level (<5g / L) to avoid the inhibitory effect of high concentration glucose on the growth and production of the strain cells. At the end of the fermentation, the yield of L-2-aminobutyric acid was 42.14g / L, the sugar-acid conversion rate reached 0.39g / g, and the space-time yield was 0.40g / L / h.

[0054] Finally, it should be noted that the above experiments and embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A genetically engineered bacterium for efficiently producing L-2-aminobutyric acid, characterized in that: The genetically engineered bacteria are obtained by knocking out the mgsA, proP, proVWX, fadR, pflB, pfkB, pykF, and amn genes on the chassis bacteria 19031-4, and overexpressing the carD, atpA, nadD, and rpoS genes.

2. The genetically engineered bacteria for efficiently producing L-2-aminobutyric acid according to claim 1, wherein: The nucleotide sequences of the mgsA, proP, proVWX, fadR, pflB, pfkB, pykF and amn genes are shown in SEQ ID NOs. 1 to 8, respectively.

3. The genetically engineered bacteria for efficiently producing L-2-aminobutyric acid according to claim 1, wherein: The nucleotide sequences of the carD, atpA, nadD and rpoS genes, and the Ptrc-carD, Ptrc-atpA, Ptrc-nadD and Ptrc-rpoS genes regulated by the trc promoter are shown in SEQ ID NOs. 9 to 12, respectively.

4. A method for constructing a genetically engineered bacterium for efficiently producing L-2-aminobutyric acid as described in any one of claims 1 to 3, characterized in that The following steps are included: S1. Knock out the gene mgsA and overexpress the gene carD in the genome of the chassis bacteria 19031-4 to obtain the engineered bacteria 19031-4derivative, mgsA::Ptrc-carD, which is recorded as the engineered bacteria ABAT1; S2, knock out the gene prop in the genome of the engineered bacteria ABAT1 to obtain the engineered bacteria ABAT1 derivative, Δprop, which is recorded as the engineered bacteria ABAT2; S3, knocking out the gene proVWX in the genome of the engineered bacterium ABAT2 to obtain the engineered bacterium ABAT2 derivative, ΔproVWX, recorded as the engineered bacterium ABAT3; S4, knocking out the gene fadR in the engineered bacteria ABAT3 to obtain the engineered bacteria ABAT3 derivative, ΔfadR, recorded as the engineered bacteria ABAT4; S5, knocking out the gene pflB in the engineered bacteria ABAT4 and overexpressing the gene atpA, obtaining the engineered bacteria ABAT4derivative, pflB::Ptrc-atpA, recorded as the engineered bacteria ABAT5; S6, overexpressing the nicotinic acid mononucleotide adenylate transferase encoding gene nadD in the genome of the engineered bacterium ABAT5 to obtain the engineered bacterium ABAT5 derivative, PnadD::Ptrc, recorded as the engineered bacterium ABAT6; S7, knocking out the gene pfkB in the genome of the engineered bacterium ABAT6 to obtain an engineered bacterium ABAT6 derivative, ΔpfkB, which is recorded as the engineered bacterium ABAT7; S8, knocking out the gene pykF in the genome of the engineered bacterium ABAT7 to obtain an engineered bacterium ABAT7 derivative, ΔpykF, which is recorded as the engineered bacterium ABAT8; S9. Knock out the amn gene and overexpress the rpoS gene in the genome of the engineered bacterium ABAT8 to obtain the engineered bacterium ABAT8derivative, amn::Ptrc-rpoS, recorded as the engineered bacterium ABAT9, which is the genetically engineered bacterium with high production of L-2-aminobutyric acid.

5. The method for constructing a genetically engineered bacterium for efficiently producing L-2-aminobutyric acid according to claim 4, characterized in that: The method for knocking out genes is CRISPR-Cas9 gene editing.

6. The method for constructing a genetically engineered bacterium for efficiently producing L-2-aminobutyric acid according to claim 5, characterized in that: The knockout vectors used to knock out genes are pCas9 and pTarget, and their nucleotide sequences are shown in SEQ ID NOs. 13 to 14, respectively.

7. Use of the genetically engineered bacteria for efficiently producing L-2-aminobutyric acid as claimed in any one of claims 1 to 3 in preparing L-2-aminobutyric acid by microbial fermentation.

8. A method for preparing L-2-aminobutyric acid, characterized in that: The steps include: S1. Inoculating the genetically engineered bacteria according to any one of claims 1 to 3 into a fermentation medium; S2, adding inducer and carrying out fermentation culture; S3. After the fermentation is completed, the fermentation liquid is taken and the supernatant is separated to obtain L-2-aminobutyric acid.

9. The method for preparing L-2-aminobutyric acid according to claim 8, characterized in that: In step S1, the genetically engineered bacteria are first cultured in LB medium overnight and then inoculated into a fermentation medium for culture.

Citation Information

Patent Citations

  • Recombinant bacteria for producing L-2-aminobutyric acid, their preparation methods and applications

    CN106148259B

  • Genetically engineered bacterium of high-yield L-2-aminobutyric acid, construction method and application

    CN114456995A

  • Method for fermentative production of L-methionine

    US20090298135A1

  • Increasing methionine yield

    US20100248311A1